Praluent
ApprovedTerminated 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Heterozygous Familial Hypercholesterolemia
Conditions
Heterozygous Familial Hypercholesterolemia, Non-familial Hypercholesterolemia
Trial Timeline
Sep 28, 2018 → Apr 8, 2020
NCT ID
NCT03694197About Praluent
Praluent is a approved stage product being developed by Sanofi for Heterozygous Familial Hypercholesterolemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03694197. Target conditions include Heterozygous Familial Hypercholesterolemia, Non-familial Hypercholesterolemia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03694197 | Approved | Terminated |
Competing Products
18 competing products in Heterozygous Familial Hypercholesterolemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0780 + Placebo | AstraZeneca | Phase 3 | 77 |
| Anacetrapib + Placebo for anacetrapib | Merck | Phase 3 | 77 |
| Enlicitide Decanoate + Placebo | Merck | Phase 2/3 | 65 |
| Inclisiran | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Fluvastatin | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Evolocumab + Placebo | Amgen | Phase 3 | 76 |
| Bococizumab (PF-04950615;RN316) | Pfizer | Phase 3 | 76 |
| Atorvastatin + Atorvastatin | Pfizer | Phase 1 | 32 |
| IBI306 + placebo | Innovent Biologics | Phase 3 | 76 |
| Lumacaftor Plus Ivacaftor Combination + Ivacaftor | Vertex Pharmaceuticals | Phase 3 | 76 |
| LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo | Sanofi | Phase 3 | 76 |
| Placebo + Alirocumab | Sanofi | Phase 3 | 76 |
| AK102 + Placebo + Statins and/or Ezetimibe | Akeso | Phase 2 | 51 |
| lerodalcibep | Medpace | Phase 3 | 74 |
| mipomersen sodium + placebo | Ionis Pharmaceuticals | Phase 3 | 74 |
| MGL-3196 (resmetirom) + Placebo | Madrigal Pharmaceuticals | Phase 2 | 49 |